Thrombolytic Therapy Side Effects: Risks and What to Expect

Thrombolytic (fibrinolytic) therapy (alteplase, tenecteplase, reteplase, streptokinase) dissolves clots in MI, ischemic stroke, PE, DVT. Benefit is time-critical; bleeding is the major risk.

Major Adverse Effects

Contraindications (Absolute/Relative)

Active bleeding, recent surgery/trauma, intracranial pathology, severe uncontrolled HTN, bleeding diathesis, pregnancy (relative for some agents).

Monitoring During/After

  • Neurologic checks q15–30min × 2h, then q1h × 24h (stroke)
  • Vitals, ECG, access site, urine output
  • Serial hemoglobin, fibrinogen, aPTT/PT
  • Immediate CT if neurologic decline

Risk-benefit favors thrombolysis in eligible acute MI/stroke/PE. Shared decision-making when margins narrow.

Blood Disorders - Related Articles

Health Sciences © https://www.222health.com

ComplicationIncidenceKey Details
Symptomatic intracranial hemorrhage (sICH)1–3% (stroke); <1% (MI)Most feared; mortality ~50%. Risk factors: age >80, severe stroke (NIHSS>10), HTN, anticoagulants, early CT changes.
Major extracranial bleeding2–5%GI, GU, retroperitoneal, access site. Transfusion-requiring.
Minor bleeding10–30%Epistaxis, gum, ecchymosis, hematuria.
HypotensionCommonVasodilation from bradykinin; usually transient. Monitor closely.
Allergic reactions1–2% (streptokinase higher)Rash to anaphylaxis. Premedicate for streptokinase.
Reperfusion arrhythmiasCommon in MIAccelerated idioventricular rhythm, VF/VT—usually self-limited.
Reperfusion injury / no-reflowVariableOxidative stress, inflammation, microvascular obstruction.
Rebound thrombosisRareParadoxical re-occlusion if underlying thrombogenic state unaddressed.